Projects per year
Personal profile
Personal profile
Dr. Bernicker earned his medical degree from Baylor College of Medicine in Houston, TX in 1990. Subsequently, he completed his residency at Baylor Affiliated Hospitals and was chief medical resident at Ben Taub General Hospital from 1993–1994. Dr. Bernicker held a faculty appointment at Baylor College of Medicine as a clinical assistant professor from 1996–2012 before joining the Houston Methodist Cancer Center in January 2013, where he serves as director of Medical Thoracic Oncology. As a physician-scientist, Dr. Bernicker oversees the expansion of clinical trials at The Methodist Hospital relating to Thoracic Oncology with all stages of disease, a combination of SWOG trials, and industry trials of novel targeted agents.
Research interests
Dr. Bernicker’s research focuses on looking at different therapeutic approaches, such as targeted therapies and immunotherapies, in the treatment of lung cancer. By understanding how to identify patients at risk for relapse after surgery or those who can be spared the toxicities of chemotherapy, the immune system can be stimulated to preferentially destroy tumor cells, spare normal tissues, and improve patient survival along with the development of less toxic therapeutics. Eventually, the goal is to be able to offer new therapies and clinical trials to patients at Methodist with any stage of non-small cell lung cancer or small cell lung cancer.
Education/Academic qualification
Medical Oncology, Clinical Fellowship, Baylor College of Medicine
Jul 1 1994 → Sep 30 1996
Award Date: Sep 30 1996
MD, Baylor College of Medicine
May 1 1990 → Jun 1 1994
Award Date: Jun 1 1994
Internal Medicine, Residency, Baylor College of Medicine
Jan 1 1991 → Jun 30 1993
Award Date: Jun 30 1993
Internship, Dallas County Hospital -Parkland Memorial Hospital
Jan 1 1990 → Jan 1 1991
Award Date: Jan 1 1991
Research Area Keywords
- Cancer
- Clinical Translation & Trials
- Clinical Care
Free-text keywords
- Cancer research
- Lung cancer
- Targeted therapeutics
Fingerprint
- 1 Similar Profiles
Network
-
An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
Singh, M., Abdelrahim, M., Bernicker, E. H., Heyne, K., Niravath, P. A. & Zhang, J.
7/25/22 → …
Project: Clinical Trial
-
A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Abdelrahim, M., Bernicker, E. H., Chang, J. C., Heyne, K., Niravath, P. A., Singh, M. & Zhang, J.
5/2/22 → …
Project: Clinical Trial
-
Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy
Bernicker, E. H., Chan, E. Y., Heyne, K., Kim, M. P., Singh, M., Sultenfuss, M. A. & Zhang, J.
9/16/21 → …
Project: Clinical Trial
-
Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer
Burns, E. A., Gee, K., Kieser, R. B., Xu, J., Zhang, Y., Crenshaw, A., Muhsen, I. N., Mylavarapu, C., Esmail, A., Shah, S., Umoru, G., Sun, K., Guerrero, C., Gong, Z., Heyne, K., Singh, M., Zhang, J., Bernicker, E. H. & Abdelrahim, M., Jan 2023, In: Cancers. 15, 1, 81.Research output: Contribution to journal › Article › peer-review
Open Access -
A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Sun, K., Xu, Y., Zhang, L., Niravath, P., Darcourt, J., Patel, T., Teh, B. S., Farach, A. M., Guerrero, C., Mathur, S., Sultenfuss, M. A., Gupta, N., Schwartz, M. R., Haley, S. L., Nair, S., Li, X., Nguyen, T. T. A., Butner, J. D., Ensor, J., Mejia, J. A., & 5 others , Oct 14 2022, In: Clinical cancer research : an official journal of the American Association for Cancer Research. 28, 20, p. 4392-4401 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Comparison of Tumor Size and Gene Expression at Presentation in Uveal Melanoma Patients before and during the COVID-19 Pandemic
Hasegawa, N., Rusakevich, A., Bernicker, E., Teh, B. S. & Schefler, A., Nov 1 2022, In: Ocular Oncology and Pathology. 8, 3, p. 156-160 5 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Contemporary trends in management of uveal melanoma
Chevli, N., Zuhour, R. J., Messer, J. A., Haque, W., Schefler, A. C., Bernicker, E. H., Chevez-Barrios, P., Farach, A. M., Butler, E. B. & Teh, B. S., 2022, In: Journal of Contemporary Brachytherapy. 14, 2, p. 123-129 7 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
Lei, X., Zhu, S., Ren, D., Ren, F., Li, T., Zhou, N., Li, S., Shi, T., Zu, L., Song, Z., Chalubinska-Fendler, J., Denis, M. G., Bernicker, E. H., de Montpréville, V. T., Jiang, R. & Xu, S., Jun 2022, In: Translational Lung Cancer Research. 11, 6, p. 1176-1184 9 p.Research output: Contribution to journal › Review article › peer-review
Open Access